Neither Blood Culture Positivity nor Time to Positivity Is Associated With Mortality Among Patients Presenting With Severe Manifestations of Sepsis: The FABLED Cohort Study

Katryn Paquette, David Sweet, Robert Stenstrom, Sarah N Stabler, Alexander Lawandi, Murtaza Akhter, Adam C Davidson, Marko Gavric, Rehman Jinah, Zahid Saeed, Koray Demir, Sassan Sangsari, Kelly Huang, Amirali Mahpour, Chris Shamatutu, Chelsea Caya, Jean-Marc Troquet, Greg Clark, Titus Wong, Cedric P Yansouni, Matthew P Cheng, Katryn Paquette, David Sweet, Robert Stenstrom, Sarah N Stabler, Alexander Lawandi, Murtaza Akhter, Adam C Davidson, Marko Gavric, Rehman Jinah, Zahid Saeed, Koray Demir, Sassan Sangsari, Kelly Huang, Amirali Mahpour, Chris Shamatutu, Chelsea Caya, Jean-Marc Troquet, Greg Clark, Titus Wong, Cedric P Yansouni, Matthew P Cheng

Abstract

Background: Sepsis is a leading cause of morbidity, mortality, and health care costs worldwide.

Methods: We conducted a multicenter, prospective cohort study evaluating the yield of blood cultures drawn before and after empiric antimicrobial administration among adults presenting to the emergency department with severe manifestations of sepsis. Enrolled patients who had the requisite blood cultures drawn were followed for 90 days. We explored the independent association between blood culture positivity and its time to positivity in relation to 90-day mortality.

Results: Three hundred twenty-five participants were enrolled; 90-day mortality among the 315 subjects followed up was 25.4% (80/315). Mortality was associated with age (mean age [standard deviation] in those who died was 72.5 [15.8] compared with 62.9 [17.7] years among survivors; P < .0001), greater Charlson Comorbidity Index (2 [interquartile range {IQR}, 1-3] vs 1 [IQR, 0-3]; P = .008), dementia (13/80 [16.2%] vs 18/235 [7.7%]; P = .03), cancer (27/80 [33.8%] vs 47/235 [20.0%]; P = .015), positive quick Sequential Organ Failure Assessment score (57/80 [71.2%] vs 129/235 [54.9%]; P = .009), and normal white blood cell count (25/80 [31.2%] vs 42/235 [17.9%]; P = .02). The presence of bacteremia, persistent bacteremia after antimicrobial infusion, and shorter time to blood culture positivity were not associated with mortality. Neither the source of infection nor pathogen affected mortality.

Conclusions: Although severe sepsis is an inflammatory condition triggered by infection, its 90-day survival is not influenced by blood culture positivity nor its time to positivity.

Clinical trials registration: NCT01867905.

Keywords: bacteremia; bloodstream infection; mortality; sepsis; survival.

© The Author(s) 2021. Published by Oxford University Press on behalf of Infectious Diseases Society of America.

Figures

Figure 1.
Figure 1.
Study flow diagram.

References

    1. Cohen J, Vincent JL, Adhikari NK, et al. . Sepsis: a roadmap for future research. Lancet Infect Dis 2015; 15:581–614.
    1. Rudd KE, Johnson SC, Agesa KM, et al. . Global, regional, and national sepsis incidence and mortality, 1990-2017: analysis for the Global Burden of Disease Study. Lancet 2020; 395:200–11.
    1. Rhodes A, Evans LE, Alhazzani W, et al. . Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock: 2016. Crit Care Med 2017; 45:486–552.
    1. Singer M, Deutschman CS, Seymour CW, et al. . The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA 2016; 315:801–10.
    1. Fleischmann C, Scherag A, Adhikari NK, et al. . International Forum of Acute Care Trialists . Assessment of global incidence and mortality of hospital-treated sepsis. Current estimates and limitations. Am J Respir Crit Care Med 2016; 193:259–72.
    1. Stevenson EK, Rubenstein AR, Radin GT, et al. . Two decades of mortality trends among patients with severe sepsis: a comparative meta-analysis. Crit Care Med 2014; 42:625–31.
    1. Seymour CW, Gesten F, Prescott HC, et al. . Time to treatment and mortality during mandated emergency care for sepsis. N Engl J Med 2017; 376:2235–44.
    1. Liu VX, Fielding-Singh V, Greene JD, et al. . The timing of early antibiotics and hospital mortality in sepsis. Am J Respir Crit Care Med 2017; 196:856–63.
    1. Kumar A, Roberts D, Wood KE, et al. . Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006; 34:1589–96.
    1. Sterling SA, Miller WR, Pryor J, et al. . The impact of timing of antibiotics on outcomes in severe sepsis and septic shock: a systematic review and meta-analysis. Crit Care Med 2015; 43:1907–15.
    1. Rhee C, Dantes R, Epstein L, et al. . CDC Prevention Epicenter Program . Incidence and trends of sepsis in US hospitals using clinical vs claims data, 2009-2014. JAMA 2017; 318:1241–9.
    1. Rannikko J, Syrjänen J, Seiskari T, et al. . Sepsis-related mortality in 497 cases with blood culture-positive sepsis in an emergency department. Int J Infect Dis 2017; 58:52–7.
    1. McCormack D, Ruderman A, Menges W, et al. . Usefulness of the Mortality in Severe Sepsis in the Emergency Department score in an urban tertiary care hospital. Am J Emerg Med 2016; 34:1117–20.
    1. Haimi-Cohen Y, Vellozzi EM, Rubin LG. Initial concentration of Staphylococcus epidermidis in simulated pediatric blood cultures correlates with time to positive results with the automated, continuously monitored BACTEC blood culture system. J Clin Microbiol 2002; 40:898–901.
    1. Cheng MP, Stenstrom R, Paquette K, et al. . FABLED Investigators . Blood culture results before and after antimicrobial administration in patients with severe manifestations of sepsis: a diagnostic study. Ann Intern Med 2019; 171:547–54.
    1. Bone RC, Balk RA, Cerra FB, et al. . Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992; 101:1644–55.
    1. Baron EJ, Weinstein MP, Dunne WM Jr, Yagupsky P, Welch DF, Wilson DM.. Cumitech 1C, blood cultures IV. Baron EJ, coordinating ed. 2005. Washington, DC: ASM Press.
    1. Kumar A, Zarychanski R, Light B, et al. . Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database Research Group . Early combination antibiotic therapy yields improved survival compared with monotherapy in septic shock: a propensity-matched analysis. Crit Care Med 2010; 38:1773–85.
    1. Yealy DM, Kellum JA, Huang DT, et al. . ProCESS Investigators . A randomized trial of protocol-based care for early septic shock. N Engl J Med 2014; 370:1683–93.
    1. Gupta S, Sakhuja A, Kumar G, et al. . Culture-negative severe sepsis: nationwide trends and outcomes. Chest 2016; 150:1251–9.
    1. Phua J, Ngerng W, See K, et al. . Characteristics and outcomes of culture-negative versus culture-positive severe sepsis. Crit Care 2013; 17:R202.
    1. Butler-Laporte G, Yansouni CP, Paquette K, et al. . Real-world time to positivity of 2 widely used commercial blood culture systems in patients with severe manifestations of sepsis: an analysis of the FABLED study. Open Forum Infect Dis 2020; 7:ofaa371.
    1. Jiang J, Yang J, Mei J, et al. . Head-to-head comparison of qSOFA and SIRS criteria in predicting the mortality of infected patients in the emergency department: a meta-analysis. Scand J Trauma Resusc Emerg Med 2018; 26:56.
    1. Motzkus CA, Luckmann R. Does infection site matter? A systematic review of infection site mortality in sepsis. J Intensive Care Med 2017; 32:473–9.
    1. Zahar JR, Timsit JF, Garrouste-Orgeas M, et al. . Outcomes in severe sepsis and patients with septic shock: pathogen species and infection sites are not associated with mortality. Crit Care Med 2011; 39:1886–95.
    1. Baron EJ, Scott JD, Tompkins LS. Prolonged incubation and extensive subculturing do not increase recovery of clinically significant microorganisms from standard automated blood cultures. Clin Infect Dis 2005; 41:1677–80.
    1. Maskarinec SA, Park LP, Ruffin F, et al. . Positive follow-up blood cultures identify high mortality risk among patients with gram-negative bacteraemia. Clin Microbiol Infect 2020; 26:904–10.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe